Chronic itch: emerging treatments following new research concepts

Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitor...

Full description

Saved in:
Bibliographic Details
Published in:British journal of pharmacology 2021-12, Vol.178 (24), p.4775-4791
Main Authors: Misery, Laurent, Brenaut, Emilie, Pierre, Ophélie, Le Garrec, Raphaele, Gouin, Olivier, Lebonvallet, Nicolas, Abasq‐Thomas, Claire, Talagas, Matthieu, Le Gall‐Ianotto, Christelle, Besner‐Morin, Catherine, Fluhr, Joachim W., Leven, Cyril
Format: Article
Language:English
Subjects:
Cannabinoid receptors
Cannabinoids
Clinical trials
Humans
itch
Life Sciences
Molecular Targeted Therapy
Neurokinin NK1 receptors
Opioid receptors
pathophysiology
Phosphodiesterase
pruritus
Pruritus - drug therapy
Receptors, Neurokinin-1
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL‐31, IL‐4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas‐related GPCRs and unexpected new pathways need to be also explored.
ISSN:0007-1188
1476-5381
DOI:10.1111/bph.15672